We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth


Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So, the natural question for Jacobio Pharmaceuticals Group (HKG:1167) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. First, we’ll determine its cash runway by comparing its cash burn with its cash reserves.

View our latest analysis for Jacobio Pharmaceuticals Group

How Long Is Jacobio Pharmaceuticals Group’s Cash Runway?

A company’s cash runway is calculated by dividing its cash hoard by its cash burn. As at December 2021, Jacobio Pharmaceuticals Group had cash of CN¥1.5b and no debt. In the last year, its cash burn was CN¥159m. Therefore, from December 2021 it had 9.7 years of cash runway. Even though this is but one measure of the company’s cash burn, the thought of such a long cash runway warms our bellies in a comforting way. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
SEHK:1167 Debt to Equity History April 29th 2022

Is Jacobio Pharmaceuticals Group’s Revenue Growing?

Given that Jacobio Pharmaceuticals Group actually had positive free cash flow last year, before burning cash this year, we’ll focus on its operating revenue to get a measure of the business trajectory. The grim reality for shareholders is that operating revenue fell by 69% over the last twelve months, which is not what we want to see in a cash burning company. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Easily Can Jacobio Pharmaceuticals Group Raise Cash?

Given its problematic fall in revenue, Jacobio Pharmaceuticals Group shareholders should consider how the company could fund its growth, if it turns out it needs more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company’s cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year’s operations.

Since it has a market capitalisation of CN¥5.2b, Jacobio Pharmaceuticals Group’s CN¥159m in cash burn equates to about 3.0% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year’s growth by issuing some new shares to investors, or even by taking out a loan.

So, Should We Worry About Jacobio Pharmaceuticals Group’s Cash Burn?

It may already be apparent to you that we’re relatively comfortable with the way Jacobio Pharmaceuticals Group is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. While we must concede that its falling revenue is a bit worrying, the other factors mentioned in this article provide great comfort when it comes to the cash burn. After taking into account the various metrics mentioned in this report, we’re pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, we conducted an in-depth investigation of the company, and identified 3 warning signs for Jacobio Pharmaceuticals Group (1 is potentially serious!) that you should be aware of before investing here.

Of course Jacobio Pharmaceuticals Group may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.



Source link

Leave a Comment

Your email address will not be published.